Aug 14, 2025, 08:03

AGA–Gastric Cancer Foundation Ben Feinstein Memorial Research Scholar Award in Gastric Cancer

Early-career faculty award supporting independent gastric cancer research with protected time (≥50% effort). Provides USD 300,000 over three years (USD 100,000/year). Research on precancerous lesions is eligible if relevance to gastric cancer is explicit.

Eligibility Criteria:

MD/PhD (or equivalent) with full-time faculty position in the U.S., Canada, or Mexico by July 2026.
Early-career status: ≤7 years since GI fellowship (MD) or since PhD conferral (PhD); documented leaves may be excluded (exemption requests due ≥3 weeks before deadline).
Basic, translational, or clinical projects; applicant self-assigns category.
AGA membership at submission and maintained throughout the 3-year term.
Sponsor and mentor required (one person may serve as both).
No prior/active comparable awards (e.g., NIH K01/K08/K23/K99/R00/R01/R21/R29, VA CDA); K12/KL2 allowed per timing rules.
Strong institutional commitment to protected time and research environment.

Funding Details:

Total: USD 300,000 (USD 100,000/year for 3 years).
Allowable: PI and key staff salary/benefits, biostatistics, supplies/animals, equipment ≤ USD 5,000/year, travel ≤ USD 1,500/year.
Not allowed: mentor salary/support; indirect costs.
Annual scientific/financial reports; years 2–3 contingent on satisfactory progress.

Deadline:

Application due: December 3, 2025.
Funding start: July 1, 2026.

Where to Go for Further Information:

Apply via the Proposal Center.
Questions: [email protected].

AGA AGA Research Foundation American Gastroenterological Association Ben Feinstein Memorial bridge awards cancer career development clinical research early-career investigators gastric cancer Gastric Cancer Foundation Gastroenterology GI oncology Hepatology OncoDaily Oncology pilot funding proposal resources protected research time Research Grants Research Scholar Award translational research upper GI

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding

Matt Sherer: ASCO Supports Permanent Medicare Telehealth